Post-tuberculosis fibrosis: Global burden and neglect.

Ayesha Patel*

Department of Pulmonary Medicine, *All India Institute of Medical Sciences* (AIIMS), India

Introduction

The landscape of post-tuberculosis lung disease (PTLD) is complex, with post-tuberculosis pulmonary fibrosis (PTBF) emerging as a significant and often debilitating sequela. Understanding the intricate mechanisms that underpin this chronic condition is paramount for developing effective therapeutic strategies and mitigating the long-term impact on global health. This body of research delves into various aspects of PTBF, from its underlying immunopathology to the role of the lung microbiome, cellular mechanisms, clinical challenges, and broader societal implications.

This review explores the immune pathways involved in post-tuberculosis pulmonary fibrosis (PTBF), highlighting how both pathogen and host factors drive chronic inflammation and progressive scarring. Deciphering these complex immunological interactions is crucial for pinpointing specific targets for intervention, ultimately aiming to prevent the irreversible lung damage that frequently follows a primary Tuberculosis (TB) infection [1].

Beyond the host's immune response, the lung microbiome also plays a significant and often overlooked role in the pathophysiology of fibrosis in post-TB lung disease. Shifts in the delicate balance of microbial communities within the lungs can actively contribute to persistent inflammation and severely hinder the natural repair processes, potentially exacerbating fibrotic outcomes and contributing to long-term lung dysfunction [2].

The broader context of pulmonary fibrosis involves intricate cellular and molecular mechanisms. This research meticulously breaks down the entire process, from the initial injury responses that trigger the cascade of events to the chronic activation of fibroblasts and the subsequent excessive deposition of extracellular matrix components. By detailing these foundational mechanisms, it lays out potential avenues for therapeutic intervention at multiple stages of fibrosis development [3].

What this really means is that pulmonary fibrosis frequently follows severe lung injury, regardless of the initial cause. This paper details the specific molecular pathways involved, illustrating how various insults can lead to progressive scarring. It provides crucial insights into the commonalities observed across different fibrotic lung diseases, suggesting shared pathogenic mechanisms that could be targeted broadly [4].

From a clinical perspective, post-tuberculosis lung disease (PTLD) demands a comprehensive understanding. This clinical review offers an extensive look at PTLD, which very often includes significant fibrotic changes. It covers the diverse ways PTLD can manifest clinically and the inherent diagnostic challenges faced by healthcare professionals, profoundly underscoring the long-term, often devastating impact of TB far beyond the initial acute infection [5].

An updated understanding of immunopathology linked specifically to tuberculosis further clarifies the disease progression. This work explains how the host immune response, while fundamentally attempting to clear the Mycobacterium tuberculosis infection, can inadvertently contribute to substantial lung damage and subsequent fibrotic remodeling. This is particularly evident in severe cases where the immune response becomes dysregulated and damaging [6].

Addressing the unique vulnerabilities of specific populations, this scoping review tackles the diagnostic and therapeutic hurdles encountered when dealing with post-tuberculosis pulmonary fibrosis in children. It emphasizes that managing fibrotic complications in younger populations necessitates specific considerations, primarily due to their developing physiology and distinct responses to disease and treatment [7].

Exploring the fundamental processes of tissue repair, this article delves into the mechanisms behind fibrosis resolution and, critically, how aging profoundly affects this complex process. Understanding why some fibrotic lesions resolve spontaneously while others relentlessly progress is a key question in respiratory pathophysiology, and the influence of age on natural healing and repair pathways is a significant, often overlooked factor [8].

For improved clinical management, the role of biomarkers in post-tuberculosis lung disease cannot be overstated. This review identifies various potential markers that could significantly aid in the diagnosis, ongoing monitoring, and prediction of outcomes for patients who develop fibrotic complications after TB. Such biomarkers pave the way for more precise and individualized clinical strategies [9].

***Correspondence to:** Ayesha Patel, Department of Pulmonary Medicine, *All India Institute of Medical Sciences* (AIIMS), India. E-mail: ayesha.patel@lungcare.in

Received: 03-Mar-2025, Manuscript No. AAJPCR-25-193; **Editor assigned:** 05-Mar-2025, Pre QC No. AAJPCR-25-193 *(PQ)*; **Reviewed:** 25-Mar-2025, QC No. AAJPCR-25-193; **Revised:** 03-Apr-2025, Manuscript No. AAJPCR-25-193 *(R)*; **Published:** 14-Apr-2025, DOI: 10.35841/aajpcr-8.2.193

Citation: Patel A. Post-tuberculosis fibrosis: Global burden and neglect. J Pulmonol Clin Res. 2025;08(02):193.

Here's the problem: post-tuberculosis lung disease (PTLD) remains a profoundly neglected global health issue. This paper emphatically highlights the massive and enduring burden of chronic lung damage, including debilitating fibrosis, that often lingers long after successful TB treatment. It affects millions worldwide, yet demands far greater attention for both research initiatives and enhanced clinical care strategies [10].

Conclusion

Post-Tuberculosis Lung Disease (PTLD), particularly post-tuberculosis pulmonary fibrosis (PTBF), presents a complex and substantial global health burden. Research consistently highlights the multifaceted nature of fibrosis development after TB infection. One key area of focus is the immunopathogenesis of PTBF, revealing how interactions between pathogens and host immune responses drive chronic inflammation and progressive scarring, ultimately leading to irreversible lung damage [1]. Beyond the immune system, the lung microbiome also plays a critical role; shifts in microbial communities contribute to chronic inflammation and hinder crucial repair processes, potentially worsening fibrotic outcomes [2].

Pulmonary fibrosis, often a consequence of severe lung injury, involves intricate cellular and molecular mechanisms, from initial injury responses to the chronic activation of fibroblasts and excessive extracellular matrix deposition [3, 4]. These pathways provide potential therapeutic targets. PTLD encompasses diverse clinical presentations and diagnostic challenges, underscoring its long-term impact [5]. An updated understanding of tuberculosis-associated immunopathology further clarifies how host immune responses, while attempting to clear infection, can inadvertently damage lung tissue and contribute to fibrotic remodeling, especially in severe cases [6].

Specific populations, such as children, face unique diagnostic and therapeutic hurdles in managing fibrotic complications due to their developing physiology [7]. Factors like aging also influence fibrosis resolution, affecting healing and repair pathways [8]. Identifying reliable biomarkers is crucial for diagnosing, monitoring, and predicting outcomes in patients with fibrotic complications post-TB [9]. Ultimately, the widespread and chronic lung damage associated with PTLD is a neglected issue, affecting millions and urgently demanding more research and clinical attention [10].

References

1. Yu L, Kun L, Yichao F. Immunopathogenesis of Post-Tuberculosis Pulmonary Fibrosis: *Current Understanding and Future Directions. Front Immunol.* 2022;13:825595.
2. Wycliffe N, Teressa N, Sammy G. The Lung Microbiome in Post-Tuberculosis Lung Disease: *A Pathophysiological Perspective on Fibrosis. Microorganisms.* 2023;12:97.
3. Zongshan M, Ruolin H, Yu Z. The cellular and molecular mechanisms of pulmonary fibrosis: from development to therapy. *Signal Transduct Target Ther.* 2024;9:17.
4. Mengying P, Yuchen W, Huan W. Pulmonary fibrosis: a common outcome of severe lung injury and its molecular mechanisms. *Cell Commun Signal.* 2022;20:179.
5. Stefano A, Nicolò S, Seona M. Post-Tuberculosis Lung Disease: *A Clinical Review. Respiration.* 2022;101:287-302.
6. Mohammed A, Stephen D, Ali A R. An Updated Review of Tuberculosis-Associated *Immunopathology. Pathogens.* 2023;12:302.
7. Seona M, Philippe C G, Frank C R. Diagnostic and Therapeutic Challenges of Post-Tuberculosis Pulmonary Fibrosis in Children: *A Scoping Review. Children* (Basel). 2022;9:556.
8. Rebecca T K, Suhas M N, *Siqiong M. Mechanisms of Fibrosis Resolution and the Impact of Aging. Front Immunol.* 2021;12:699039.
9. Niccolò B, Giorgia M, Mirko M. Biomarkers in Post-Tuberculosis Lung Disease: *A Scoping Review. J Clin Med.* 2023;12:4853.
10. Sai R, Anjali M, Akshat G. Post-tuberculosis lung disease (PTLD)-The neglected global problem. *Front Public Health.* 2022;10:1008684.

Citation: *Patel A. Post-tuberculosis fibrosis: Global burden and neglect. J Pulmonol Clin Res. 2025;08(02):193.*